

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 December 2021 (16.12.2021)



(10) International Publication Number
WO 2021/252878 A1

- (51) International Patent Classification:
C07K 16/10 (2006.01) *A61P 31/14* (2006.01)
- (21) International Application Number:
PCT/US2021/036979
- (22) International Filing Date:
11 June 2021 (11.06.2021)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
- | | | |
|------------|------------------------------|----|
| 63/038,738 | 12 June 2020 (12.06.2020) | US |
| 63/066,966 | 18 August 2020 (18.08.2020) | US |
| 63/141,430 | 25 January 2021 (25.01.2021) | US |
| 63/159,404 | 10 March 2021 (10.03.2021) | US |
| 63/186,055 | 07 May 2021 (07.05.2021) | US |
| 63/196,089 | 02 June 2021 (02.06.2021) | US |
- (71) Applicant: **VIR BIOTECHNOLOGY, INC.** [US/US];
499 Illinois Street, Suite 500, San Francisco, California
94158 (US).
- (72) Inventors: **ALEXANDER, Elizabeth**; 499 Illinois Street,
Suite 500, San Francisco, California 94158 (US). **YEH,
Wendy**; 499 Illinois Street, Suite 500, San Francisco, Cal-
ifornia 94158 (US). **PANG, Phillip S**; 499 Illinois Street,
Suite 500, San Francisco, California 94158 (US). **HONG,
David**; 499 Illinois Street, Suite 500, San Francisco, Cal-
ifornia 94158 (US). **CONNOLLY, Lynn E.**; 499 Illinois
Street, Suite 500, San Francisco, California 94158 (US).
MONGALIAN, Erik; 499 Illinois Street, Suite 500, San
Francisco, California 94158 (US). **SAGAR, Jenny**; 499
Illinois Street, Suite 500, San Francisco, California 94158
(US). **SMITHEY, Megan**; 499 Illinois Street, Suite 500,
San Francisco, California 94158 (US).
- (74) Agent: **MORGAN, John, A.** et al.; Seed Intellectual Prop-
erty Law Group LLP, Suite 5400, 701 Fifth Avenue, Seat-
tle, Washington 98104-7064 (US).

(54) Title: ANTIBODY THERAPIES FOR SARS-COV-2 INFECTION




FIG. 1

(57) Abstract: The instant disclosure provides methods of treating or preventing a SARS-CoV-2 infection, e.g., in a subject having or at risk for developing COVID-19, using an antibody (or antigen-binding fragment) compositions. Disclosed methods include prophylaxis against SARS-CoV-2 infection or transmission, as well as treatment of a subject having a SARS-CoV-2 infection. A SARS-CoV-2 infection (e.g., causing COVID-19) to be treated can be at any stage of infection and/or can result in any stage of disease, for example, mild, mild-to-moderate, severe, or critical.

[Continued on next page]

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))